MOSCOW May 16. 2024 (Saba) - Director of the Joint Center for Genetic Technologies at Belgorod National Research University, Alexei Dekin, announced that the world's first drug for the treatment of myopathy has successfully passed preclinical tests.
The Russian news agency TASS quoted Dekin on Thursday as saying: "Scientists intend this year to submit a request to the Ministry of Health for approval to conduct clinical tests on patients.
Deakin noted that myopathy (Mushin atrophy) is a rare advanced disease that occurs in people over the age of 35. This is due to the lack of protein responsible for the integrity of muscle cells.
"The drug was developed in partnership with Artgen Biotech, and we proposed a way to treat the disease by delivering the gene that codes the missing protein to muscle cells in two ways: using viruses or associated plasmids.
The researchers studied both forms of the drug in terms of efficacy and safety."
Z.E
resource : Saba
| more of (International) |